Alkermes plc

-0.18 (-0.74%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)3.90B
Current PEN/A
Forward PE 50.63
2yr Forward PE 26.7
See more stats
Estimates Current Quarter
Revenue$276.93 Million
Adjusted EPS$0.12
See more estimates
10-Day MA$24.23
50-Day MA$23.90
200-Day MA$20.78
See more pivots

Alkermes plc Stock, NASDAQ:ALKS

Connaught House, 1 Burlington Road, Dublin, Dublin 4
Phone: +353.1.772.8000
Number of Employees: 2245


Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.